---
title: CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
date: '2024-11-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39555828/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241119173555&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In this phase 1 study involving patients with ATTR-CM,
  treatment with a single dose of nex-z was associated with transient infusion-related
  reactions and consistent, rapid, and durable reductions in serum TTR levels. (Funded
  by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number,
  ...'
disable_comments: true
---
CONCLUSIONS: In this phase 1 study involving patients with ATTR-CM, treatment with a single dose of nex-z was associated with transient infusion-related reactions and consistent, rapid, and durable reductions in serum TTR levels. (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, ...